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Requests for Abortion in Latin America Related to Concern 
about Zika Virus Exposure
To the Editor: On November 17, 2015, the Pan 
American Health Organization (PAHO) issued 
an epidemiologic alert regarding Zika virus in 
Latin America.1 Several countries subsequently 
issued health advisories, including cautions 
about microcephaly, declarations of national 
emergency, and unprecedented warnings urging 
women to avoid pregnancy. Yet in most Latin 
American countries, abortion is illegal or highly 
restricted,2 leaving pregnant women with few 
options.
For several years, one such option for women 
in Latin America has been Women on Web 
(WoW), a nonprofit organization that provides 
access to abortion medications (mifepristone 
and misoprostol) outside the formal health care 
setting through online telemedicine in countries 
where safe abortion is not universally available.3 
We analyzed data with respect to requests for 
abortion through WoW between January 1, 
2010, and March 2, 2016, in 19 Latin American 
countries. Using a regression-discontinuity de-
sign, we assessed whether requests for abortion 
increased after the PAHO alert, as compared 
with preannouncement trends.
We classified requests according to self-re-
ported country of origin and divided countries 
into three groups: group A, with autochthonous 
Zika transmission, legally restricted abortion, 
and national public advisories to pregnant wom-
en; group B, with no autochthonous Zika trans-
mission and legally restricted abortion; and 
group C, with autochthonous Zika transmis-
sion, legally restricted abortion, and no national 
advisories. We also included three control coun-
tries — Chile, Poland, and Uruguay — in which 
no increase in requests related to Zika virus in-
fection was expected. (Details are provided in 
the Supplementary Appendix, available with the 
full text of this letter at NEJM.org.) During the 
final 3 study weeks, women were asked specifi-
cally if they were seeking abortion because of 
concern about Zika virus infection. In their re-
sponse, women did not confirm whether they 
had received a diagnosis of such infection.
In all group A countries except Jamaica, there 
were statistically significant increases of 36 to 
108% over baseline in requests for abortion 
through WoW after the PAHO announcement 
(Table 1, and Fig. S3 in the Supplementary Ap-
pendix). In group B, small increases were ob-
served in two countries, Argentina and Peru. In 
the latter, officials sparked concern about Zika 
virus infection by asking the government to 
declare a preemptive state of emergency.4 No 
significant increases were observed in group C 
or in any control countries. We cannot defini-
tively attribute the rapid acceleration in requests 
in group A to concern about Zika virus expo-
sure. However, the percentage of women in each 
country who reported such concern as their 
reason for seeking abortion correlates with the 
observed country-specific increases in requests 
over baseline trends (Table S1 in the Supplemen-
tary Appendix).
In Latin American countries that issued 
warnings to pregnant women about complica-
tions associated with Zika virus infection, re-
quests for abortion through WoW increased 
significantly. Our approach may underestimate 
the effect of the advisories on demand for abor-
tion, since many women may have used an un-
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Country
Actual 
Requests
Expected 
 Requests
Relative Change 
between Actual 
and Expected 
Requests P Value
number %
Group A: autochthonous Zika virus transmission, le-
gally restricted abortion, and national pregnan-
cy advisory
Brazil 1210 581.7 108.0 <0.001
Colombia 141 101.7 38.7 <0.001
Costa Rica 67 49.2 36.1 0.04
El Salvador 24 17.7 35.6 0.01
Ecuador 71 34.2 107.7 <0.001
Honduras 36 20.5 75.7 <0.001
Jamaica 25 37.2 −32.9 0.65
Venezuela 86 44.5 93.3 <0.001
Group B: No autochthonous Zika virus transmission, 
legally restricted abortion
Argentina 270 221.7 21.8 0.004
Bahamas 15 10.5 42.8 0.28
Peru 81 67.2 20.5 0.04
Trinidad and Tobago 12 10.0 20.6 0.70
Group C: autochthonous Zika virus transmission, le-
gally restricted abortion, no national pregnancy 
advisory
Bolivia 21 12.5 68.4 0.17
Dominican Republic 17 21.2 −20.0 0.61
Guatemala 32 29.5 8.4 0.65
Mexico† 172 184.4 −6.7 0.98
Nicaragua 11 8.8 24.3 0.81
Panama 21 17.3 21.3 0.12
Paraguay 16 12.8 24.5 0.36
Control group
Chile 442 463.4 −4.6 0.98
Uruguay 5 5.1 −1.0 0.85
Poland 1574 1487.7 5.8 0.73
*  Actual requests are cumulative counts for the period from November 17, 2015, when the Pan American Health 
Organization (PAHO) issued an epidemiologic alert regarding Zika virus in Latin America, to March 2, 2016. Expected 
requests were obtained as forecasts on the basis of the null model for each country on the assumption that there 
would be no discontinuity after the PAHO announcement. P values were calculated by means of a likelihood-ratio test 
of the regression-discontinuity model versus the null model of no discontinuity.
†  Abortion is highly restricted in Mexico except in the capital, the Federal District, where first-trimester abortion was de-
criminalized in 2007.
Table 1. Number of Online Requests for Abortion Medications after the PAHO Alert Regarding Zika Virus Exposure, 
According to Country.*
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safe method, accessed misoprostol from local 
pharmacies or the black market, or visited local 
underground providers. But accurate data on 
these choices are difficult to obtain.5 Thus, our 
data provide a window on how concern about 
Zika virus infection may have affected the lives 
of pregnant women in Latin America.
Models that were developed by the World 
Health Organization predict that 3 million to 4 
million persons across the Americas (including 
North America, Central America, South Ameri-
ca, and the Caribbean) will contract Zika virus 
infection through early 2017, and the virus will 
inevitably spread to other countries where access 
to safe abortion is restricted. Official informa-
tion and advice about potential exposure to the 
Zika virus should be accompanied by efforts to 
ensure that all reproductive choices are safe, le-
gal, and accessible.
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